• Explore /
  • Poster
  • / Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.

Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.

Abstract Poster

Authors

null

Michael Y. Choi

University of California San Diego Moores Cancer Center, La Jolla, CA

Michael Y. Choi , William G. Wierda , Hun Ju Lee , Dimitrios Tzachanis , Xen Ianopulos , Deborah Jezior , James Bradley Breitmeyer , Catriona HM Jamieson , Thomas J. Kipps

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT03420183

Citation

J Clin Oncol 37, 2019 (suppl; abstr 7527)

DOI

10.1200/JCO.2019.37.15_suppl.7527

Abstract #

7527

Poster Bd #

281

Abstract Disclosures

Similar Posters

First Author: Hun Ju Lee

First Author: Hun Ju Lee

First Author: Prithviraj Bose

First Author: David Lavie